Roquefort Therapeutics plc

OTCPK:ROQA.F Stock Report

Market Cap: US$8.8m

Roquefort Therapeutics Past Earnings Performance

Past criteria checks 0/6

Roquefort Therapeutics has been growing earnings at an average annual rate of 5.7%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 100% per year.

Key information

5.7%

Earnings growth rate

-3.5%

EPS growth rate

Biotechs Industry Growth17.0%
Revenue growth rate-100.0%
Return on equity-31.3%
Net Marginn/a
Last Earnings Update30 Jun 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Roquefort Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:ROQA.F Revenue, expenses and earnings (GBP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 240-210
31 Mar 240-210
31 Dec 230-221
30 Sep 230-221
30 Jun 230-221
31 Mar 230-210
31 Dec 220-210
30 Jun 220-110
31 Mar 220-100
31 Dec 210-100

Quality Earnings: ROQA.F is currently unprofitable.

Growing Profit Margin: ROQA.F is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if ROQA.F's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare ROQA.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ROQA.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).


Return on Equity

High ROE: ROQA.F has a negative Return on Equity (-31.28%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies